PharmiWeb Recruiter Blog

As 2023 draws to a close, we wanted to take a moment to express our gratitude for your support during what has been a challenging year for the life science industry.

Healthcare intelligence organisation earns recognition as employer of choice and leading innovator in the clinical trial industry

Building on expertise in RSV prevention, acquisition will accelerate ambition to deliver portfolio of protective interventions to address high unmet needs in infectious diseases

• A new research team at the BioMed X Institute will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease.

Heidelberg, November 7, 2023. BioMed X, an independent biomedical research institute, announced yesterday the launch of a Call for Application in immunology. This call aims to assemble a new research team to develop innovative strategies for neutralizing autoreactive plasma cells in the context of autoimmune disease.

• Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche’s in-house assets
• Lead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbidities
• Under the terms of the agreement, Roche will pay a purchase price of USD 2.7 billion upfront and additional milestone payments of up to USD 400 million

Basel, 4 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. (“Carmot”), a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

• Evinova will operate as a separate health-tech business within AstraZeneca
• Evinova’s globally-scaled digital health solutions are evidence-led, science-based and human experience-driven to serve clinical trial sponsors, clinical research organisations (CROs), clinical trial site care teams and patients
• First strategic collaborations with globally-leading CROs Parexel and Fortrea enable Evinova’s digital health solutions to be offered to their wide customer base

AstraZeneca today launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the life sciences and healthcare sector. 

-- The companies expand the scope of their existing collaboration for CART-ddBCMA to include lymphomas --

Bagsværd, Denmark, 10 November 2023 – Novo Nordisk today announced plans to invest more than 42 billion Danish kroner starting in 2023¹ to expand existing manufacturing facilities in Kalundborg, Denmark, for the current and future product portfolio within serious chronic diseases.

As a recruitment professional in the life science industry, employee referral programs (ERPs) are a highly effective way of expanding your talent pool, identifying high-quality candidates, and engaging both active and passive talent.

The Global Talent Lab, in partnership with XTX Markets and the UK Department for Science, Innovation, and Technology (DSIT), proudly introduces the BIG UK Programme. This initiative is designed to identify and nurture global talent, positioning them to push the boundaries in mathematics, science, and AI.